Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

First Boehringer and now Merck ‘gamifies’ clinical research

Kaggle challenge set up to help pharma company develop safe and effective medicines

- PMLiVE

Merck misses revenue targets as Singulair slumps

Asthma drug hit hard by generic competition in the US

- PMLiVE

Sanofi nearing end of patent cliff, says Viehbacher

Higher third-quarter revenues see pharma company raise forecasts for 2012

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

UK flag

UK could allow patented drugs to be used in clinical trials

Government proposes update to Patents Act to restrict when companies can sue for infringement

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

- PMLiVE

Indonesia breaks seven HIV, hepatitis drug patents

Merck & Co, GSK, Gilead, Abbott and BMS all effected

- PMLiVE

Merck & Co relocates global headquarters

Leaves Whitehouse Station for new site in New Jersey

- PMLiVE

India revokes Pfizer’s patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

- PMLiVE

MSF unveils website to help pharma patent challengers

Patent Opposition Database contains patents facing opposition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links